Sunday, December 10, 2017
Saturday, December 09, 2017
Friday, December 08, 2017
Hospitalization with infection as a particular risk factor for VTE
Highlights
•Hospitalized infection appears to trigger VTE events.•The triggering effect of infection on VTE decreases over time after an infection.•VTE preventive measures may prevent VTE events in the peri-infection period.•Hospitalized patients with an infection may be considered for VTE prophylaxis.
Thursday, December 07, 2017
Wednesday, December 06, 2017
GIK for myocardial infarction
We refuse to give up
on it but haven’t quite found a way to make it work, and it’s
been 40 years now. The latest? If you couple it with tight glycemic control in NSTEMI, then maybe.
Tuesday, December 05, 2017
Should drug eluting (as opposed to bare metal) stents be used in patients with atrial fibrillation?
Another way of
asking this might be “how long do you want to subject a patient to
triple anti-thrombotic therapy?”
There is not a clear
evidence based answer. This study looked at practice patterns
and there is considerable variation.
Monday, December 04, 2017
Sunday, December 03, 2017
Saturday, December 02, 2017
Friday, December 01, 2017
Thursday, November 30, 2017
Hyperammonemic encephalopathy following bariatric surgery
You can add this one
to two growing lists: bariatric surgery complications and non
hepatic hyperammonemias. [1] [2]
Mechanisms? From
the first reference:
The specific mechanisms driving the hyperammonemic state after RYGB may be multifactorial. As it has been almost exclusively observed in women, X-linked partial ornithine transcarbamylase (OTC) deficiency has been implicated (Figure 2). Previously asymptomatic heterozygous OTC-deficient women can present when faced with catabolic stressors, and biochemical profiling is consistent with impaired urea cycle function. Zinc deficiency has also been proposed to interfere with OTC function (5). Nongenetic mechanisms of increased ammoniagenesis have been considered, including portosystemic shunting, severe hepatic dysfunction, and overgrowth of intestinal flora. A profound catabolic state may also play a role, driving protein breakdown and accumulation of nitrogenous waste products.
Wednesday, November 29, 2017
HRCT scanning in the diagnosis of pulmonary diseases
In diffuse or
multifocal parenchymal lung disease the HRCT may point to a specific
diagnosis or place the disorder in a category, thus shortening the
differential. Free full text review.
Tuesday, November 28, 2017
Monday, November 27, 2017
Hospitalists as housekeepers
Hospitalists write medication orders, take calls for “housekeeping” issues and do the discharge paperwork. With us, quality of care and patient satisfaction generally improve, and the surgeon isn’t being called at 2 a.m. with requests for Tylenol or laxatives. What’s not to like?
How did we get into
this mess? By failing to set boundaries to limit the mission creep
that moved us away from the original notion of hospitalists as
clinicians within the original scope of their training, IMHO. Our
professional organization didn’t help.
Sunday, November 26, 2017
Saturday, November 25, 2017
The hospital of tommorrow
Hospitalists will be
obsolete as the hospital care team continues home care via
telemedicine and putting patients to death will be considered patient
centered. Read the rest.
Friday, November 24, 2017
Clinical status before and outcomes after admission to hospice
Background
Prior work has shown that symptoms leading to restrictions in daily activities are common at the end of life. Hospice is a Medicare benefit designed to alleviate distressing symptoms in the last 6 months of life. The effect of hospice on the burden of such symptoms is uncertain.Methods
From an ongoing cohort study of 754 community-dwelling older persons, aged greater than or equal to 70 years, we evaluated 241 participants who were admitted to hospice from March 1998 to December 2013. A set of 15 physical and psychological symptoms leading to restricted activity (ie, cut down on usual activities or spend at least half the day in bed) were ascertained during monthly telephone interviews in the year before and 3 months after hospice admission.
Results
The prevalence and mean number of restricting symptoms increased progressively until about 2 months before hospice admission, before increasing precipitously to a peak around the time of hospice admission. After the start of hospice, both the prevalence and the mean number of restricting symptoms dropped markedly. For several symptoms deemed most amenable to hospice treatment, including depression and anxiety, the prevalence dropped to levels comparable to or lower than those observed 12 months before the start of hospice. The trends observed in symptom prevalence and mean number of symptoms before and after hospice did not differ appreciably according to hospice admission diagnosis or sex. The median duration of hospice (before death) was only 15 days.
Conclusion
The burden of restricting symptoms increases progressively several months before the start of hospice, peaks around the time of hospice admission, and decreases substantially after the start of hospice. These results, coupled with the short duration of hospice, suggest that earlier referral to hospice may help to alleviate the burden of distressing symptoms at the end of life.
Thursday, November 23, 2017
Wednesday, November 22, 2017
Home NPPV
Question Does the addition of home noninvasive ventilation to home oxygen therapy prolong time to readmission or death for patients with chronic obstructive pulmonary disease and persistent hypercapnia following a life-threatening exacerbation?
Findings In this randomized clinical trial of 116 patients, the addition of home noninvasive ventilation significantly prolonged time to readmission or death from 1.4 months to 4.3 months.
Meaning The addition of home noninvasive ventilation to home oxygen therapy may improve outcomes in patients with severe chronic obstructive pulmonary disease and persistent hypercapnia following hospital admission.
Tuesday, November 21, 2017
An attempted classification to encompass the diverse phenotypes of diabetes
The different forms
of diabetes no longer lend them selves to two simple categories.
Various efforts to refine the classification have been met with
controversy and complicated by evolving understanding. Here is my
attempt to summarize the current thinking.
Type 1: caused by
complete autoimmune destruction of the beta cells. A good practical
definition is that patients require exogenous insulin in order to
stay alive. That is, they will invariably develop ketoacidosis (DKA)
when deprived of insulin, even in the basal state.
It is important to specify
the basal state, because patients with other forms of diabetes can go
into DKA as well, but only in the presence of some stressor such as
sepsis, MI, stroke, etc. This
designation has changed little in recent decades and remains useful,
though it has seen some tweaks as noted below.
Type 1b aka 1.5: These
designations are no longer very
useful for a variety or
reasons. They originally
(especially 1b)
referred to a group of patients in certain ethnic groups with
phenotypic characteristics of both type 1 and type 2 diabetes who
seemingly transitioned from type 1 to type 2 and/or back, due
to a non autoimmune mechanism: intermittent reversible severe beta
cell failure due to an exaggerated form of glucotoxicity. This
group has subsequently been found to be more heterogeneous than
previously thought, both in terms of ethnicity and pathogenesis. To
confuse things further, these terms (especially
1.5) have also been used to
denote late autoimmune diabetes of adulthood (LADA), an unrelated
condition. The terms were partially
replaced in popular usage with ketosis prone type 2 diabetes but
that too has been waning in
popularity, largely
abandoned. The ADA,
recognizing that there are patients who develop DKA but lack
antibodies, created the category of “idiopathic type 1 diabetes.”
A more recently proposed
category recognizes the heterogeneity in these patients (and
subclassifies them accordingly) and is known as ketosis prone
diabetes (see below). To
confuse things a bit, KPD also incorporates patients who do not fit
this phenotype, in order to
encompass all diabetic patients who go into ketoacidosis apart from
some severe stress.
(Note: a very early designation for
patients seemingly transitioning between the phenotypes of DM 1 and 2
was Flatbush diabetes).
Ketosis
prone diabetes (KPD): This is a proposed designation to replace
the category immediately above and
adds some other mechanisms,
attempting to encompass all patients who spontaneously develop DKA.
It recognizes the heterogeneity of the phenotype above,
specifically the fact that
some forms have an autoimmune pathogenesis. Its
4 categories are based on the presence or absence of beta cell
reserve and the presence or absence of autoimmunity.
Type
2: DM 2 is pretty well defined and I will not spend a great deal of
time here other than to caution against defining it as any case of
diabetes that does not develop DKA in the basal state. That is to
say that some forms of diabetes, that don’t invariably cause DKA in
the basal state, are not appropriately classified as DM 2 as will be
discussed below. Although DM
2 is itself heterogeneous the patients have in common insulin
resistance, gradual beta cell fatigue and the metabolic syndrome.
Type
3: Here’s where it gets
even more confusing. While
often a wastebasket there are some forms of diabetes that rightfully
belong in this category though in current literature they have varied
and sometimes quite limited degrees of acceptance. There are
numerous subcategories. Here they are.
Type
3, no letter designation: This is a theoretical construct that Alzheimer
disease is essentially diabetes (insulin resistance) localized to the
brain and might be effectively treated with insulin sensitizing
agents.
Additional
categories of DM 3, designated by letter, were taken from this site:
Type 3 A refers to
genetic defects in beta cells, essentially MODY. Inheritance is
monogenic autosomal dominant as opposed to the polygenic inheritance
of DM 2.
Type 3 B refers to
severe genetically determined insulin resistance as seen in Donohue syndrome and related disorders.
Type 3 C is a more
accepted category and denotes diabetes due to damage to the pancreas
as a whole, eg pancreatitis, pancreatic cancer or pancreatic trauma.
[1] [2]. This is important because it is usually
misdiagnosed as DM 2 yet has unique treatment implications.
Type 3 D is DM
caused by other endocrinopathies eg Cushing’s.
Type 3 E refers to
DM caused by drugs such as corticosteroids.
Type 3 F refers to
DM caused by infection. In the cite referenced above congenital
rubella was given as the example. Would Hep C fit in here?
Type 3 G refers to
diabetes associated with unusual autoimmune diseases, eg stiff person
syndrome.
Type 3 H refers to
diabetes associated with Down’s syndrome.
Note: Although all
the entities mentioned above under type 3 are real I could find
little or no independent support in the literature for the
nomenclature except for the one with no letter designation
(Alzheimer disease) and type 3C.
Type 4 This is a
theoretical construct based on an animal model, attempting to
explain some instances of apparent DM 2 in lean adults. This may not
be an important entity in man if it exists at all and might be
confused with LADA.
Miscellaneous forms:
Latent autoimmune
diabetes in adults (LADA). It is sometimes been referred to as DM
1.5.
Double diabetes.
You could be unlucky and have both 1 & 2. Or, in DM 1, if you
treat overeating with more and more and more insulin and thereby gain
of sufficient weight the characteristics of DM 2 could develop
secondarily.
Subscribe to:
Posts (Atom)